Compare Amphastar Pharmaceuticals Inc (AMPH) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs KKR & Co Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while KKR & Co Inc trades at $111.14 (market cap $93.20B). The key difference: KKR & Co Inc is far larger — about 107.9× Amphastar Pharmaceuticals Inc's market cap, and KKR & Co Inc pays a 0.75% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KKR | |
|---|---|---|
Market Cap | $863.95M | $93.20B |
Sector | Health | Financials |
52-Week High | $30.81 | $149.34 |
52-Week Low | $16.87 | $83.88 |
Enterprise Value | $1.26B | $15.76B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
KKR trades at $102.81, down 0.52% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.63 per share, beating estimates, and maintains robust analyst support with a consensus price target of $127.22. Recent news highlights active deal-making, including the acquisition of Integer Holdings and the closing of a $19.2 billion infrastructure fund, signaling growth momentum.
The outlook for KKR is positive, driven by earnings beats, strategic acquisitions, and strong institutional sentiment. Key risks include execution of large deals, market volatility, and interest rate sensitivity. The stock presents an opportunity for growth-oriented investors, supported by a high buy rating consensus and expanding asset management operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
